Aptamers as imaging agents

Expert Opinion on Medical Diagnostics

Volumn 4, Issue 6, 2010, Pages 511-518

  Gomes, Sonia Da Rocha ^a   Azéma, Laurent ^b   Allard, Michle ^b   Toulmé, Jean Jacques ^b,c  

^a Novaptech   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSTITUT EUROPÉEN DE CHIMIE ET BIOLOGIE   (France)

Author keywords

aptamer; chemical modifications; diagnostic; imaging probes; SELEX; tumor imaging

Indexed keywords

APTAMER; NX 21909; QUANTUM DOT; TECHNETIUM 99M; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

CHEMICAL MODIFICATION; COLORIMETRY; COMBINATORIAL CHEMISTRY; CONJUGATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; FLUORESCENCE; HUMAN; ISOTOPE LABELING; NONHUMAN; REVIEW;

EID: 78649273661     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2010.516248     Document Type: Review

References (68)

1. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990;249(4968):505-10
2. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990;346(6287):818-22
3. Robertson DL, Joyce GF. Selection in vitro of an RNA enzyme that specifically cleaves single-stranded DNA. Nature 1990;344(6265):467-8
4. Tuerk C, MacDougal S, Gold L. RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci USA 1992;89(15):6988-92
5. Bock LC, Griffin LC, Latham JA, et al. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992;355(6360):564-6
6. Toulme JJ, Darfeuille F, Kolb G, et al. Modulating viral gene expression by aptamers to RNA structures. Biol Cell 2003;95(3-4):229-38
7. Blank M, Blind M. Aptamers as tools for target validation. Curr Opin Chem Biol 2005;9(4):336-42
8. Stoltenburg R, Reinemann C, Strehlitz B. SELEX-a (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 2007;24(4):381-403
9. Gopinath SC. Antiviral aptamers. Arch Virol 2007;152(12):2137-57
10. Morris KN, Jensen KB, Julin CM, et al. High affinity ligands from in vitro selection: complex targets. Proc Natl Acad Sci USA 1998;95(6):2902-7
11. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999;45(9):l628-50
12. Bunka DH, Stockley PG. Aptamers come of age-at last. Nat Rev Microbiol 2006;4(8):588-96
13. Mayer G. The chemical biology of aptamers. Angew Chem Int Ed Engl 2009;48(15):2672-89
14. Ng EW, Shima DT, Calias P, et al. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006;5(2):123-32
15. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007;ll6(23):2678-86
16. Darfeuille F, Hansen JB, Orum H, et al. LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1. Nucleic Acids Res 2004;32(10):3101-7
17. Kuwahara M, Obika S, Takeshima H, et al. Smart conferring of nuclease resistance to DNA by 3'-end protection using 2',4'-bridged nucleoside-5'- triphosphates. Bioorg Med Chem Lett 2009;19(ll):294l-3
18. Kasahara Y, Kitadume S, Morihiro K, et al. Effect of 3'-end capping of aptamer with various 2',4'-bridged nucleotides: enzymatic post-modification toward a practical use of polyclonal aptamers. Bioorg Med Chem Lett 2010;20(5):l626-9
19. Kang J, Lee MS, Copland JA III, et al. Combinatorial selection of a single stranded DNA thioaptamer targeting TGF-betall protein. Bioorg Med Chem Lett 2008;18(6):1835-9
20. Appella DH. Non-natural nucleic acids for synthetic biology. Curr Opin Chem Biol 2009;13(5-6):687-96
21. Keefe AD, Cload ST. SELEX with modified nucleotides. Curr Opin Chem Biol 2008;12(4):448-56
22. Takahashi M, Minakawa N, Matsuda A. Synthesis and characterization of 2'-modified-4'-thioRNA: a comprehensive comparison of nuclease stability. Nucleic Acids Res 2009;37(4):1353-62
23. Zaitseva M, Kaluzhny D, Shchyolkina A, et al. Conformation and thermostability of oligonucleotide d(GGTTGGTGTGGTTGG) containing thiophosphoryl internucleotide bonds at different positions. Biophys Chem 2010;l46(l):l-6
24. Andreola ML, Calmels C, Michel J, et al. Towards the selection of phosphorothioate aptamers optimizing in vitro selection steps with phosphorothioate nucleotides. Eur J Biochem 2000;267(l6):5032-40
25. Ruckman J, Green LS, Beeson J, et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273(32):20556-67
26. White RR, Roy JA, Viles KD, et al. A nuclease-resistant RNA aptamer specifically inhibits angiopoietin-1-mediated Tie2 activation and function. Angiogenesis 2008;11(4):395-401
27. White RR, Shan S, Rusconi CP, et al. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA 2003;100(9):5028-33
28. Chelliserrykattil J, Ellington AD. Evolution of a T7 RNA polymerase variant that transcribes 2'-0-methyl RNA. Nat Biotechnol 2004;22(9):1155-60
29. Hocek M, Fojta M. Cross-coupling reactions of nucleoside triphosphates followed by polymerase incorporation. Construction and applications of base-functionalized nucleic acids. Org Biomol Chem 2008;6(13):2233-4l
30. Li M, Lin N, Huang Z, et al. Selecting aptamers for a glycoprotein through the incorporation of the boronic acid moiety. J Am Chem Soc 2008;130(38):12636-8
31. Hicke BJ, Stephens AW, Gould T, et al. Tumor targeting by an aptamer. J Nucl Med 2006;47(4):668-78
32. Da Pieve C, Perkins AC, Missailidis S. Anti-MUCl aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice. Nucl Med Biol 2009;36(6):703-10
33. Nutiu R, Li Y. Structure-switching signaling aptamers. J Am Chem Soc 2003;125(l6):4771-8
34. Wu C, Yan L, Wang C, et al. A general excimer signaling approach for aptamer sensors. Biosens Bioelectron 2010;25(10):2232-7
35. Kuhnast B, de Bruin B, Hinnen F, et al. Design and synthesis of a new [18F] fluoropyridine-based haloacetamide reagent for the labeling of oligonucleotides: 2-bromo-N-[3-(2-[18F] fluoropyridin-3-yloxy)propyl]acetamide. Bioconjug Chem 2004;15(3):6l7-27
36. Hwang do W, Ko HY, Lee JH, et al. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med 2010;51(1):98-105
37. Tong R, Yala L, Fan TM, Cheng J. The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells. Biomaterials 2010;31(ll):3043-53
38. Farokhzad OC, Karp JM, Langer R. Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin Drug Deliv 2006;3(3):311-24
39. Farokhzad OC, Cheng J, Teply BA, et al. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006 103;(l6):6315-20
40. Zhou J, Soontornworajit B, Martin J, et al. A hybrid DNA aptamer-dendrimer nanomaterial for targeted cell labeling. Macromol Biosci 2009;9(9):831-5
41. Kim Y, Dennis DM, Morey T, et al. Engineering dendritic aptamer assemblies as superior inhibitors of protein function. Chem Asian J 2010;5(l):56-9
42. Javier DJ, Nitin N, Levy M, et al. Aptamer-targeted gold nanoparticles as molecular-specific contrast agents for reflectance imaging. Bioconjugate Chem 2008;19(6):1309-12
43. Wu Y, Sefah K, Liu H, et al. DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc Natl Acad Sci USA 2010;107(1):5-10
44. Bagalkot V, Zhang L, Levy-Nissenbaum E, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 2007;7(10):3065-70
45. Levy M, Cater SF, Ellington AD. Quantum-dot aptamer beacons for the detection of proteins. Chembiochem 2005;6(12):2l63-6
46. Dassie JP, Liu XY, Thomas GS, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009;27(9):839-49
47. Kolb HC, Finn MG, Sharpless KB. Click chemistry: diverse chemical function from a few good reactions. Angew Chem Int Ed Engl 2001;40(11):2004-21
48. Singh I, Heaney F. Metal free, 'click and click-click' conjugation of ribonucleosides and 2'-OMe oligoribo nucleotides on the solid phase. Org Biomol Chem 2010;8(2):451-6
49. Da Pieve C, Williams P, Haddleton DM, et al. Modification of thiol functionalized aptamers by conjugation of synthetic polymers. Bioconjugate Chem 2010;21(l):l69-74
50. Lupoid SE, Hicke BJ, Lin Y, Coffey DS. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res 2002;62(l4):4029-33
51. Chu TC, Shieh F, Lavery LA, et al. Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. Biosens Bioelectron 2006;21(10):1859-66
52. Al-Jamal WT, Al-Jamal KT, Bomans PH, et al. F unctionalized-quantum-dot- lipo so me hybrids as multimodal nanoparticles for cancer. Small 2008;4(9):l406-15
53. Pestourie C, Tavitian B, Duconge F. Aptamers against extracellular targets for in vivo applications. Biochimie 2005;87(9-10):921-30
54. Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 2006; 103 (32):11838-43
55. Herr JK, Smith JE, Medley CD, et al. Ap tamer-conjugated nanoparticles for selective collection and detection of cancer cells. Anal Chem 2006;78(9):2918-24
56. Smith JE, Medley CD, Tang Z, et al. Ap tamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal Chem 2007;79(8):3075-82
57. Nobile V, Russo N, Hu G, Riordan JF. Inhibition of human angiogenin by DNA aptamers: nuclear colocalization of an angiogenin-inhibitor complex. Biochemistry 1998;37(19):6857-63
58. Li W, Yang X, Wang K, et al. Real-time imaging of protein internalization using aptamer conjugates. Anal Chem 2008;80(13):5002-8
59. Charlton J, Kirschenheuter GP, Smith D. Highly potent irreversible inhibitors of neutrophil elastase generated by selection from a randomized DNA-valine phosphonate library. Biochemistry 1997;36(10):3018-26
60. Bless NM, Smith D, Charlton J, et al. Protective effects of an aptamer inhibitor of neutrophil elastase in lung inflammatory injury. Curr Biol 1997;7(ll):877-80
61. Charlton J, Sennello J, Smith D. In vivo imaging of inflammation using an aptamer inhibitor of human neutrophil elastase. Chem Biol 1997;4(11):809-16
62. Hicke BJ, Marion C, Chang YF, et al. Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 2001;276(52):48644-54
63. Ferreira CS, Matthews CS, Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUCl-binding single-stranded DNA aptamers. Tumour Biol 2006;27(6):289-301
64. Majumdar D, Peng XH, Shin DM. The medicinal chemistry of theragnostics, multimodality imaging and applications of nanotechnology in cancer. Curr Top Med Chem 2010;10(12):1211-26
65. Borbas KE, Ferreira CS, Perkins A, et al. Design and synthesis of mono-and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUCl aptamers for the diagnostic imaging and targeted radiotherapy of cancer. Bioconjug Chem 2007;18(4):1205-12
66. Gramlich PM, Warncke S, Gierlich J, Carell T. Click-click-click: single to triple modification of DNA. Angew Chem Int Ed 2008;47(18):3442-4
67. Kele P, Mezo G, Achatz D, Wolfbeis OS. Dual labeling of biomolecules by using click chemistry: a sequential approach. Angew Chem Int Ed 2009;48(2):344-7
68. Trussel S, Dumelin C, Frey K, et al. New strategy for the extension of the serum half-life of antibody fragments. Bioconjugate Chem 2009;20(12):2286-92